Apnimed Announces Upcoming Oral Presentation at SLEEP 2026 to Highlight Pooled Phase 3 Data for AD109 in Obstructive Sleep Apnea
PR Newswire
CAMBRIDGE, Mass., June 10, 2026
CAMBRIDGE, Mass., June 10, 2026 /PRNewswire/ -- Apnimed, Inc., a late stage clinical pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced that six abstracts have been selected for presentation, including an oral presentation, at the upcoming SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), being held from June 14th to 17th at the Baltimore Convention Center. Certain abstracts being presented will feature a pooled analysis of the SynAIRgy and LunAIRo Phase 3 trials of AD109, Apnimed's lead product candidate, reflecting one of the largest clinical development programs conducted for an obstructive sleep apnea pharmacotherapy. Other research underscores substantial unmet needs in OSA, marked by persistent diagnostic delays and high proportion of diagnosed patients who remain untreated, highlighting an urgent need to improve awareness and education.
